Cargando…

Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma

BACKGROUND: Cholangiocarcinoma (CCA) is a highly aggressive and fatal tumor. CCA occurs in the epithelial cells of bile ducts. Due to increasing incidences, CCA accounts for 3% of all gastrointestinal malignancies. In addition to comprehensive treatments for cancer, such as surgery, chemotherapy, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alnaggar, Mohammed, Xu, Yan, Li, Jingxia, He, Junyi, Chen, Jibing, Li, Man, Wu, Qingling, Lin, Li, Liang, Yingqing, Wang, Xiaohua, Li, Jiawei, Hu, Yi, Chen, Yan, Xu, Kecheng, Wu, Yangzhe, Yin, Zhinan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368763/ https://www.ncbi.nlm.nih.gov/pubmed/30736852 http://dx.doi.org/10.1186/s40425-019-0501-8

Ejemplares similares

Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer
por: Xu, Yan, et al.
Publicado: (2020)

Chitosan Nanoparticles Strengthen Vγ9Vδ2 T-Cell Cytotoxicity Through Upregulation Of Killing Molecules And Cytoskeleton Polarization
por: Lin, Li, et al.
Publicado: (2019)

Irreversible electroporation plus allogenic Vγ9Vδ2 T cells enhances antitumor effect for locally advanced pancreatic cancer patients
por: Lin, Mao, et al.
Publicado: (2020)

Allogeneic Vγ9Vδ2 T-Cell Therapy Promotes Pulmonary Lesion Repair: An Open-Label, Single-Arm Pilot Study in Patients With Multidrug-Resistant Tuberculosis
por: Liang, Juan, et al.
Publicado: (2021)

An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer
por: Lin, Mao, et al.
Publicado: (2017)

Hepatocellular carcinoma‐infiltrating γδ T cells are functionally defected and allogenic Vδ2(+) γδ T cell can be a promising complement
por: He, Wenjing, et al.
Publicado: (2022)

Comparison of autogeneic and allogeneic natural killer cells immunotherapy on the clinical outcome of recurrent breast cancer
por: Liang, Shuzhen, et al.
Publicado: (2017)

Iodine-125 seed implantation and allogenic natural killer cell immunotherapy for hepatocellular carcinoma after liver transplantation: a case report
por: Xie, Silun, et al.
Publicado: (2018)

Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer
por: Lin, Mao, et al.
Publicado: (2017)

Human Umbilical Cord Mesenchymal Stem Cells Inhibit the Function of Allogeneic Activated Vγ9Vδ2 T Lymphocytes In Vitro
por: Liu, Xiaohuan, et al.
Publicado: (2015)

Vitamin C promotes the proliferation and effector functions of human γδ T cells
por: Kouakanou, Léonce, et al.
Publicado: (2019)

Quantitative assessment of disease markers using the naked eye: point-of-care testing with gas generation-based biosensor immunochromatographic strips
por: Fu, Qiangqiang, et al.
Publicado: (2019)

CAR-Modified Vγ9Vδ2 T Cells Propagated Using a Novel Bisphosphonate Prodrug for Allogeneic Adoptive Immunotherapy
por: Wang, Yizheng, et al.
Publicado: (2023)

Phosphoantigens glue butyrophilin 3A1 and 2A1 to activate Vγ9Vδ2 T cells
por: Yuan, Linjie, et al.
Publicado: (2023)

Dendritic Cells Are Critical for the Activation and Expansion of Vδ2(+) T Cells After Allogeneic Hematopoietic Transplantation
por: Wang, Xiaoyu, et al.
Publicado: (2018)

Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy
por: Du, Shou-Hui, et al.
Publicado: (2016)

IDO Inhibition Facilitates Antitumor Immunity of Vγ9Vδ2 T Cells in Triple-Negative Breast Cancer
por: Li, Peng, et al.
Publicado: (2021)

Allogenic natural killer cell immunotherapy of sizeable ovarian cancer: A case report
por: Xie, Silun, et al.
Publicado: (2017)

Mapping of γ/δ T cells reveals Vδ2+ T cells resistance to senescence
por: Xu, Weili, et al.
Publicado: (2018)

Long-term response of metastatic renal clear cell carcinoma following a subcutaneous injection of mixed bacterial vaccine: a case report
por: Chen, Jibing, et al.
Publicado: (2019)

Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering
por: Lee, Derek, et al.
Publicado: (2023)

Combined chemotherapy and allogeneic human Vγ9Vδ2 T lymphocyte-immunotherapies efficiently control the development of human epithelial ovarian cancer cells in vivo
por: Joalland, Noémie, et al.
Publicado: (2019)

Characteristics of peripheral Vγ2Vδ2 T cells in interferon-γ release assay negative pulmonary tuberculosis patients
por: Yan, Liping, et al.
Publicado: (2018)

Overexpression of 14-3-3δ Predicts Poor Prognosis in Extrahepatic Cholangiocarcinoma Patients
por: Wu, Qiao, et al.
Publicado: (2020)

Sensing of Pyrophosphate Metabolites by Vγ9Vδ2 T Cells
por: Gu, Siyi, et al.
Publicado: (2015)

Role of Vγ9vδ2 T lymphocytes in infectious diseases
por: Gay, Laetitia, et al.
Publicado: (2022)

Beneficial Effect of Antibiotics and Microbial Metabolites on Expanded Vδ2Vγ9 T Cells in Hepatocellular Carcinoma Immunotherapy
por: Han, Jiajia, et al.
Publicado: (2020)

Phenotype and functional changes of Vγ9/Vδ2 T lymphocytes in Behçet's disease and the effect of infliximab on Vγ9/Vδ2 T cell expansion, activation and cytotoxicity
por: Accardo-Palumbo, Antonina, et al.
Publicado: (2010)

B7-H3 inhibits the IFN-γ-dependent cytotoxicity of Vγ9Vδ2 T cells against colon cancer cells
por: Lu, Huimin, et al.
Publicado: (2020)

Brain Metastases Completely Disappear in Non-Small Cell Lung Cancer Using Hydrogen Gas Inhalation: A Case Report
por: Chen, Jibing, et al.
Publicado: (2019)

Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer
por: Hoeres, Timm, et al.
Publicado: (2018)

Development and Selection of the Human Vγ9Vδ2(+) T-Cell Repertoire
por: Willcox, Carrie R., et al.
Publicado: (2018)

The PPARα pathway in Vγ9Vδ2 T cell anergy
por: Poupot, Mary, et al.
Publicado: (2014)

Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy
por: Ridgley, Laura A., et al.
Publicado: (2023)

Control of CD56 expression and tumor cell cytotoxicity in human Vγ2Vδ2 T cells
por: Urban, Elizabeth M, et al.
Publicado: (2009)

Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T Cell
por: Yang, Rui, et al.
Publicado: (2022)

Apoptosis, Pyroptosis, and Ferroptosis Conspiringly Induce Immunosuppressive Hepatocellular Carcinoma Microenvironment and γδ T-Cell Imbalance
por: Hu, Yi, et al.
Publicado: (2022)

Generation of Stable Isopentenyl Monophosphate Aryloxy Triester Phosphoramidates as Activators of Vγ9Vδ2 T Cells
por: Xu, Qin, et al.
Publicado: (2021)

γδ T cells: origin and fate, subsets, diseases and immunotherapy
por: Hu, Yi, et al.
Publicado: (2023)

Perioperative management of intrahepatic cholangiocarcinoma patients with hereditary coagulation factor V deficiency: a case report and literature review
por: Lai, Jianlin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_repo7saipdr6n2mgeqqujo5lac